secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tenaya Therapeutics, Inc. (TNYA)
CIK:        0001858848
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0000950170-23-040628
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenaya Q2 net loss $33.3M; TN-201 first patient dosing on track for Q3 2023
---------------------------------------------------------------------------

- Cash and investments $151.6M; runway into first half 2025.
- R&D expense $26.5M; G&A expense $8.6M; net loss $0.45/share.
- First patient in MyPeak-1 Phase 1b trial of TN-201 expected in Q3 2023.
- Data from TN-301 Phase 1 trial accepted for HFSA October 2023.
- IND for TN-401 PKP2 gene therapy planned for H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858848/000095017023040628/0000950170-23-040628-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858848/000095017023040628/tnya-20230809.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-040628

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer